How much funding has Padlock Therapeutics raised?

Padlock Therapeutics has raised $23.0M in total funding, most recently a Series A round.

Who are Padlock Therapeutics's investors?

Padlock Therapeutics's investors include Bristol Myers Squibb, Atlas Venture.

When was Padlock Therapeutics founded?

Padlock Therapeutics was founded in 2014.

Where is Padlock Therapeutics headquartered?

Padlock Therapeutics is headquartered in Cambridge, Massachusetts, United States.

What industry is Padlock Therapeutics in?

Padlock Therapeutics operates in Biotech.

Padlock Therapeutics

Closed

Cambridge, United States · Founded 2014 · $23.0M raised

Biotech

Headquarters: Cambridge, Massachusetts
Founded: 2014
Business Model: B2B

Total Funding: $23.0M
Last Round: $23.0M Series ADec 2014
Rounds: 1

About

Padlock Therapeutics was a Cambridge, Massachusetts-based biotechnology company founded in 2014 to develop novel small-molecule and biologic medicines targeting protein arginine deiminase (PAD) enzymes implicated in autoimmune diseases such as rheumatoid arthritis and lupus. The company was acquired by Bristol-Myers Squibb in April 2016 for up to $600 million, expanding BMS's autoimmune disease pipeline.

Summary

Padlock Therapeutics is a Biotech company based in Cambridge, United States, founded in 2014. It has raised $23.0M in total across 1 round, most recently a $23.0M Series A round in Dec 2014. Investors include Bristol Myers Squibb and Atlas Venture.